Peter WT Pisters, M.D., president of UT MD Anderson, said the honorees represent the institution’s commitment to excellence in research, patient care, prevention and education. Their work reflects the increasingly integrated nature of modern oncology, in which progress depends not only on developing new drugs, but also on understanding tumor biology, identifying patients most likely to benefit from particular interventions, improving radiation delivery, expanding access to prevention programs and designing safer systems of care. Together, these efforts support MD Anderson’s mission to end cancer and extend the reach of advances to patients and communities worldwide.

The Jack and Beverly Randall Prize for Excellence in Cancer Care, which carries a $100,000 award, was presented this year to Hilary Ma, M.D., a professor in General Oncology. Established in 2011 by Jack and Beverly Randall, the prize recognizes vision and creativity in cancer research and clinical care, alternating annually between researchers and clinicians. The award reflects the growing importance of care models that combine scientific innovation with practical clinical judgment. In oncology, breakthroughs become meaningful only when they can be delivered safely, equitably and efficiently to people facing complex diseases, often alongside surgery, radiation, systemic therapy and supportive care.

Jeffrey Gershenwald, M.D., professor of Surgical Oncology, and Mark Bedford, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, received the R. Lee Clark Prize. The award, established in 2016 through the estate of Jeanne F. Shelby, honors one faculty member in clinical research and one in basic or translational research. Gershenwald’s surgical oncology field focuses on the clinical management of cancer, while Bedford’s discipline investigates epigenetic regulation, the molecular systems that influence how genes are activated or silenced without changing the underlying DNA sequence. Such research can reveal why tumors behave differently and may identify vulnerabilities for future therapies.

The Shirley Stein Scientific Endowed Research Award went to Ethan Lin, M.D., assistant professor of Interventional Radiology, and Hongxia Sun, M.D., Ph.D., associate professor of Anatomic Pathology. The award provides $10,000 for preliminary data generation, a critical stage in the development of clinical research programs. Early data can help investigators test whether a hypothesis is biologically plausible, refine study methods and build the evidence needed to compete for larger federal or institutional grants. Interventional radiology uses image-guided procedures to diagnose or treat disease with minimally invasive techniques, while anatomic pathology examines tissues and cells to establish diagnoses and characterize the biological features of tumors.

Katy Rezvani, M.D., Ph.D., vice president and head of the Institute for Cell Therapy Discovery & Innovation, received the President’s Award for Leadership Excellence. She is also a professor of Stem Cell Transplantation and Cellular Therapy. The award combines the former John Mendelsohn Award for Faculty Leadership and the Charles A. LeMaistre Outstanding Achievement Award in Cancer. Her area of work is part of a rapidly developing branch of oncology in which immune cells are collected, engineered or otherwise prepared to recognize malignant cells. Cellular therapies require close coordination among laboratory scientists, manufacturing specialists, transplant teams and clinical investigators, making institutional leadership essential to moving discoveries from research settings into patient care.

Six faculty members were named Faculty Scholars, a program recognizing assistant and associate professors with exceptional potential in research, education, patient care or prevention. The honorees are Hussein Abbas, M.D., Ph.D., assistant professor of Leukemia; Scherezade Mama, Dr.P.H., associate professor of Health Disparities Research; Amy Moreno, M.D., assistant professor of Radiation Oncology; Van Morris, M.D., associate professor of Gastrointestinal Medical Oncology; Natalie Vokes, M.D., assistant professor of Thoracic Head and Neck Medical Oncology; and Tao Wang, Ph.D., associate professor of Bioinformatics and Computational Biology. Their fields illustrate how cancer medicine increasingly depends on interdisciplinary expertise, including population science, radiation physics, disease-specific treatment and data analysis.

Bioinformatics and computational biology are particularly important as cancer research generates vast quantities of genomic, imaging and clinical information. Computational approaches can help researchers compare tumor samples, identify patterns associated with treatment response and organize complex data into testable biological models. Health disparities research, meanwhile, examines how social, economic, geographic and structural factors influence exposure to risk, access to screening and the likelihood of receiving timely, high-quality care. By recognizing both areas alongside disease-focused specialties, the Faculty Scholar Program reflects a broader view of cancer control that includes biology, technology and the conditions in which patients live.

The Faculty Achievement Awards honored six additional faculty members for original contributions across basic science, prevention, clinical research, education, patient care and translational research. Betty Kim, M.D., Ph.D., professor of Neurosurgery, received the basic science research award. Sanjay Shete, Ph.D., professor of Biostatistics, was recognized for cancer prevention. Rodabe Amaria, M.D., professor of Melanoma Medical Oncology, received the clinical research award, while Phyu Aung, M.D., Ph.D., professor of Anatomic Pathology, was honored for education. Peter Balter, Ph.D., professor of Radiation Physics, received the patient care award, and Tina Cascone, M.D., Ph.D., associate professor of Thoracic Head and Neck Medical Oncology, was recognized for translational research.

The range of disciplines represented by the awards underscores the complex pathway from discovery to medical impact. Basic science can identify mechanisms that drive tumor growth; biostatistics can determine whether an observed result is reliable; prevention research can reduce risk before cancer develops; and clinical trials can establish whether a promising intervention benefits patients. Radiation physics contributes to the precision and safety of treatment planning, while pathology provides the diagnostic and molecular information needed to classify disease. Translational research connects these stages by testing how findings from laboratories, models and early studies can be adapted to real-world clinical practice.

The celebration also recognized faculty excellence in quality improvement and patient safety, research, community engagement, education and mentorship. These areas may receive less public attention than dramatic laboratory discoveries, but they are essential to dependable cancer care. Quality improvement uses systematic measurement to identify weaknesses in clinical processes and test changes that improve outcomes. Patient-safety programs seek to prevent avoidable harm by examining communication, medication use, procedures and institutional workflows. Community engagement and education can strengthen prevention and early detection, while mentorship helps sustain the next generation of investigators and clinicians. Through its awards and promotions, UT MD Anderson presented cancer progress as a collective enterprise in which scientific innovation, clinical expertise and institutional responsibility are inseparable.

Subject of Research: Cancer research, oncology, cancer prevention, cellular therapy, clinical care, medical education and patient safety.

Article Title: UT MD Anderson Honors Faculty Advancing Cancer Research, Care and Prevention

News Publication Date: August 20, 2026

Web References: UT MD Anderson Cancer Center; https://www.mdanderson.org/

References: University of Texas MD Anderson Cancer Center, Celebration of Faculty Excellence announcement.

Image Credits: UT MD Anderson

Keywords: cancer research, oncology, cancer prevention, faculty awards, UT MD Anderson, clinical research, translational research, cellular therapy, bioinformatics, patient care, health disparities, radiation oncology, cancer education

Schimmer joins OICR after serving as Director of Research at University Health Network’s Princess Margaret Cancer Centre, where he remains a longtime clinician-scientist. His career has focused especially on blood cancers, including leukemia, a group of diseases in which abnormal blood-forming cells multiply uncontrollably and interfere with the production of healthy red blood cells, white blood cells and platelets. Research in this field requires a close connection between molecular biology, clinical medicine and patient care, because the genetic and cellular features of a leukemia can influence how it develops, responds to therapy and eventually becomes resistant to treatment.

With more than 320 peer-reviewed publications and approximately 27,000 citations, Schimmer is one of Canada’s most prominent leukemia researchers. His scientific work has contributed to a broader understanding of the biological mechanisms that drive blood cancers and the challenges involved in developing more effective therapies. In modern oncology, such research often combines genomic analysis, laboratory models, drug testing and clinical investigation to identify vulnerabilities in cancer cells while limiting harm to healthy tissue. This approach is central to precision medicine, which seeks to match treatments to the biological characteristics of an individual patient’s disease.

The new OICR leader also brings extensive experience in the organization and delivery of research. He is a Professor in the University of Toronto’s Departments of Medicine, Medical Biophysics and Institute of Medical Science, and has served as President of the Canadian Hematology Society. He is a Fellow of the Royal Society of Canada. These roles have connected him to researchers, physicians, trainees and health-care institutions across Ontario and nationally, relationships that may help OICR coordinate research programs across disciplines and accelerate collaboration between academic laboratories, hospitals and technology developers.

“After years of close collaboration with OICR, I can attest to the transformative impact the Institute has had on cancer research in Ontario and around the world,” Schimmer said. “I am honoured and humbled to help lead this outstanding organization as we deliver life-changing solutions to the biggest challenges in cancer.” His comments reflect the increasingly collaborative nature of cancer science, where progress often depends not on a single laboratory but on networks that can share data, biological samples, clinical expertise and specialized technologies.

Schimmer takes on the role as OICR launches its Strategic Plan 2026–2031. The plan is intended to shape the institute’s priorities during a period when cancer research is being transformed by advances in genomics, artificial intelligence, imaging, immunology and targeted drug development. These technologies are expanding scientists’ ability to examine tumours at high resolution, track changes over time and distinguish between cancer subtypes that may appear similar under a microscope but behave very differently in the body. Translating these findings into routine care, however, requires rigorous validation, clinical trials, regulatory oversight and equitable access.

Cancer research is now at what Schimmer describes as a watershed moment, with opportunities to improve how cancers are detected, diagnosed and treated. Earlier detection can increase the likelihood that a tumour is found before it spreads, while more precise diagnosis can help physicians select therapies according to a cancer’s molecular profile. Treatment research is also moving beyond conventional approaches that directly kill rapidly dividing cells. New strategies may involve directing the immune system against malignant cells, blocking specific molecular signals or combining therapies to prevent resistant cancer populations from surviving.

For Ontario, the potential benefits extend beyond medicine. OICR is funded by the Government of Ontario and is expected to support research that improves the health of residents while contributing to the province’s life-sciences economy. Cancer research can generate economic activity through biotechnology development, clinical trials, specialized manufacturing, data science and the creation of new diagnostic and therapeutic technologies. The challenge is to ensure that promising discoveries move efficiently through the research pipeline and ultimately become tools that can be used by patients and health-care professionals.

“With world-class research talent, infrastructure and collaborations led by OICR, and the strong support of the Provincial Government, Ontario is poised to lead the next generation of cancer innovations,” Schimmer said. He added that OICR has a unique ability to accelerate cancer research across the province while producing benefits for people living with cancer and for future generations. His leadership will begin as the institute works to implement its new strategic plan and strengthen the connections required to turn scientific ideas into real-world solutions.

“Cancer research is at a watershed moment, full of unprecedented opportunities to transform how cancers are detected, diagnosed and treated,” Schimmer said. “I look forward to working with everyone in the OICR community to write the next chapter for OICR and for cancer research in this province.” The institute’s stated mission is to take on major challenges in cancer research and deliver practical advances that help find cancer earlier and treat it more effectively.

Subject of Research: Cancer research, leukemia, precision medicine and the translation of scientific discoveries into improved cancer detection, diagnosis and treatment.

Article Title: Aaron Schimmer Begins Tenure as President and Scientific Director of Ontario Cancer Research Institute

News Publication Date: August 4, 2026

Keywords: Aaron Schimmer, Ontario Institute for Cancer Research, OICR, leukemia, hematology, cancer research, precision medicine, oncology, cancer innovation, University of Toronto, Princess Margaret Cancer Centre, Strategic Plan 2026–2031

At the same time, cancer prevention research is getting a literal upgrade in operational realism. Sylvester’s Firefighter Cancer Initiative partnered with Florida Forest Service cadets to complete wildland firefighter training, strengthening the “worker-centered” evidence pipeline. The effort aims to capture the full complexity of exposure pathways, physical demands, and real-world variability—factors that often blur epidemiology and limit the precision of prevention strategies.

For pancreatic cancer, attention is moving toward the inflammatory signaling machinery that tumors hijack to resist therapy. Researchers targeting IL1RAP, a receptor acting as a shared conduit for multiple inflammatory messages, report that disrupting this helper pathway can weaken the tumor-driven network that supports treatment resistance. JCI Insight findings are now paving the way for a neoadjuvant clinical trial pairing IL1RAP-targeted therapy with chemotherapy in operable patients before surgery.

Complementing this drug-target approach, a new tumor-on-a-chip platform offers a live view of how pancreatic cancer reorganizes its microenvironment. Developed through a Sylvester–Miller School of Medicine–College of Engineering collaboration, the Biofabrication study uses microengineered conditions to observe recruitment and behavior of immune cells over time, identifying vulnerabilities that could make existing treatments more effective.

Sex differences in glioblastoma biology are also coming into sharper focus. A Sylvester-led Nature Cancer study mapped a critical immune pathway that fuels tumor growth specifically in female models. The work shows that the neurotransmitter GABA enhances tumor-protective immune-cell activity in females, and that blocking this GABA-driven immune suppression improves outcomes—suggesting a route to more tailored therapies.

Clinically, hope is being tested through precision interventions as well. A patient with glioblastoma turned to Laser Interstitial Thermal Therapy, a minimally invasive technique that can ablate tumor tissue with high spatial control. The case underscores how surgical technology and patient-specific planning increasingly shape brain-cancer trajectories.

Finally, outreach efforts show how scientific momentum can extend beyond the bench. Dani’s Promise, founded by a teen inspired by her mother’s triple-negative breast cancer journey, supplies comfort items to patients undergoing chemotherapy at Sylvester, with plans to expand to additional locations.

In aggregate, these stories highlight a research ecosystem where AI prediction, exposure-informed prevention, inflammation-targeted therapeutics, immune-aware modeling, and sex-specific mechanisms converge—producing the kind of viral, mechanism-forward headlines that define next-wave cancer science.

Keywords: sarcoma, bone fractures, AI imaging, wildland firefighting, pancreatic cancer, IL1RAP, tumor-on-a-chip, glioblastoma, GABA, cancer immunology

Dr. Ibrahim’s role will be pivotal in bridging the gap between discovery science and patient-centered application by driving forward developmental therapeutic strategies. She will collaborate closely with oncologists throughout the HonorHealth system to improve patient access to novel clinical trials and foster collaborative partnerships with premier biomedical research entities globally. This integrative approach is designed to accelerate the translation of emergent cancer therapies from experimental stages to standard-of-care treatments.

With years of experience spanning academic oncology, translation research, and pharmaceutical drug development, Dr. Ibrahim brings unparalleled expertise in multiple facets of cancer therapeutics. Her training includes hematology, oncology, and specialized fellowships focusing on melanoma and breast cancer. She has held prestigious faculty roles at institutions including Harvard Medical School’s Dana-Farber Cancer Institute and the University of Pennsylvania’s Abramson Cancer Center. These roles enriched her understanding of tumor biology, immune-oncology mechanisms, and translational medicine.

In the pharmaceutical arena, Dr. Ibrahim distinguished herself as Vice President of Global Clinical Development in Oncology at Merck. In this capacity, she played an instrumental role in the clinical and regulatory advancement of Keytruda (pembrolizumab), an immune checkpoint inhibitor that has transformed the treatment landscape for many cancers. Her leadership was integral to the drug’s approval across a variety of oncologic indications including melanoma, Merkel cell carcinoma, gastrointestinal malignancies, hepatobiliary cancers, and tumors characterized by specific biomarkers such as MSI-High and TMB-High status, which indicate heightened tumor mutational burden and mismatch repair deficiency.

Dr. Ibrahim’s expertise encompasses a broad range of therapeutic modalities, extending beyond immunotherapy to include targeted therapies, antibody-drug conjugates (ADCs), and small molecule inhibitors. Her comprehensive understanding of the mechanism of action, pharmacodynamics, and resistance pathways of these modalities enables strategic development of combination regimens aimed at overcoming cancer heterogeneity and treatment resistance — a critical challenge in oncology drug development.

In 2025, Dr. Ibrahim founded Arc Nouvel Clinical Development Consulting, a boutique consultancy aimed at guiding pharmaceutical, biotechnology, and investment stakeholders through the increasing complexity of oncology drug development. Leveraging a seasoned network of clinical development experts, the consultancy provides strategic advisory services, operational support, asset evaluation, and leadership coaching for drug programs spanning from early discovery to late-stage clinical trials. This entrepreneurial endeavor emphasizes tactical innovation and precision medicine approaches in oncology.

While maintaining her leadership role at Arc Nouvel, Dr. Ibrahim is committed to applying the same principles of scientific rigor and operational excellence to HonorHealth Research Institute. Her dual roles empower synergistic opportunities, linking academic research with pragmatic drug development strategies to expedite the introduction of groundbreaking therapies to clinical practice. This alignment reflects her broader vision of cancer research as an integrated ecosystem spanning academia, biotech, and clinical care settings.

Under her stewardship, the developmental therapeutics and immuno-oncology program at HonorHealth will emphasize not only discovery and therapeutic innovation but also equitable and streamlined patient access. By expanding the institute’s clinical trial portfolio across multiple tumor types and geographic regions, Dr. Ibrahim ensures diverse patient participation and the generation of robust clinical data reflective of real-world populations. This is crucial in enabling regulatory approvals and optimizing treatment guidelines.

HonorHealth Research Institute itself stands as a leader in oncology clinical research, leveraging multidisciplinary collaborations with experts nationwide. Situated in Scottsdale, Arizona, the institute offers patients unprecedented access to novel drugs, devices, and treatment strategies emerging from cutting-edge research. Its mission centers on improving patient outcomes and quality of life through participation in rigorous, randomized controlled clinical trials — the gold standard for clinical evidence generation.

The return of Dr. Ibrahim to a research-focused leadership position highlights the increasing importance of translational science and immuno-oncology in cancer therapeutics. Her deep expertise in biomarker-driven development and immune response modulation is especially relevant as personalized medicine continues transforming oncology care. Therapies that harness the immune system’s ability to target cancer cells and overcome tumor immune evasion mechanisms are leading the future of cancer treatment.

HonorHealth encourages patients and referring physicians to engage with their clinical trial programs to explore enrollment opportunities. Through comprehensive patient-centric research protocols, the institute aims to shift the oncology treatment paradigm — transforming incurable malignancies into manageable or even curable conditions. Dr. Ibrahim’s appointment marks a dynamic step forward in aligning research capabilities with urgent unmet clinical needs in cancer care.

For further information on clinical trials at HonorHealth Research Institute, interested parties may contact the institute directly via phone at 833-354-6667 or email clinicaltrials@HonorHealth.com. This outreach ensures that novel therapeutic options are accessible to those who may benefit most while also supporting the broader scientific community’s understanding of cancer biology and treatment response variability.

This strategic recruitment of Dr. Nageatte Ibrahim symbolizes HonorHealth’s ongoing commitment to institutional excellence and innovation. By integrating outstanding scientific talent with patient-centered clinical research infrastructure, HonorHealth Research Institute aims to remain at the forefront of oncology advancements well into the future.

Subject of Research: People

Article Title: International Oncology Leader Dr. Nageatte Ibrahim Joins HonorHealth to Advance Cancer Therapeutics and Immuno-Oncology Innovation

News Publication Date: June 4, 2026

Web References: https://www.honorhealth.com/company/research-institute; http://arcnouvel.com/

Keywords: oncology drug development, immuno-oncology, cancer therapeutics, clinical trials, Keytruda, pembrolizumab, developmental therapeutics, biomarker-driven therapy, melanoma, personalized medicine, antibody-drug conjugates, cancer research

At the core of organoid technology is its ability to maintain the multifaceted tumor microenvironment, including diverse cellular populations and extracellular matrix components that are often lost in simpler in vitro models. Recent advances in culture engineering and biomaterials have been instrumental in stabilizing tumor phenotypes and enhancing the interpretability of drug screening data. Synthetic matrices, decellularized extracellular scaffolds, and scaffold-free culture systems, combined with dynamic perfusion bioreactors, are increasingly deployed to mimic in vivo conditions, ensuring the preservation of critical biophysical and biochemical cues that govern tumor behavior and drug sensitivities.

The tumor microenvironment itself is a complex ecosystem, comprising cancer-associated fibroblasts, immune effectors, vascular networks, and extracellular matrix remodeling enzymes—all of which deeply influence tumor progression and therapeutic resistance. To faithfully reconstruct these intricate interactions, researchers have developed sophisticated co-culture strategies that integrate stromal and immune cells alongside tumor organoids. This holistic approach enables robust modeling of tumor–host interactions and provides a more physiologically relevant context for functional phenotyping, essential for translational applications.

Translation of tumor organoids from bench to bedside is further driven by cutting-edge technologies that enhance scalability and standardization. Organoids-on-chip platforms facilitate precise microenvironmental control and real-time monitoring, while three-dimensional bioprinting enables reproducible generation of complex tissue architectures. High-throughput miniaturized screening combined with multi-omics data integration and machine learning analytics empowers rigorous functional drug-response profiling, accelerating the identification of personalized therapeutic regimens with clinical relevance.

Despite these remarkable advances, the field grapples with critical issues of reproducibility and translatability. Variability in culture protocols and biomaterials can cause divergent tumor states and drug responses, underscoring the necessity for integrated quality control and cross-laboratory standardization. Developing universal benchmarks for organoid phenotypic stability and assay validation remains a paramount goal, as uniformity is indispensable in converting these models into reliable decision-making tools.

Equally pressing are ethical considerations surrounding the sourcing and use of patient-derived tissues. Proper governance frameworks must encompass consent processes, data privacy, and equitable access to emerging therapies informed by organoid platforms. As organoids become increasingly embedded in clinical pipelines, fostering transparent ethical standards will underpin responsible deployment and public trust in this transformative technology.

The living-biosensor framework posited in recent research encapsulates the multifaceted potential of tumor organoids, unifying mechanistic experimentation, microenvironmental recapitulation, and functional drug response into an integrative platform for precision oncology. By situating organoid technology as both a discovery engine and a clinical decision aide, this paradigm offers a practical roadmap from model establishment to therapeutic translation, embodying a new frontier in cancer medicine.

Looking forward, the convergence of biomaterials science, tissue engineering, and computational analytics holds promise to refine organoid systems further, enhancing their physiological relevance and scalability. Multi-disciplinary collaboration will be key to overcoming remaining technical and biological hurdles. Prospective studies harmonizing organoid-derived biomarker discovery with patient outcomes will validate their prognostic and predictive value, ultimately informing tailored treatment regimens that improve survival and quality of life.

In conclusion, tumor organoids represent a transformative leap in cancer research, providing a living, patient-specific platform that recapitulates tumor complexity and enables functional drug testing with clinical fidelity. Through advances in biomaterials, microenvironment reconstruction, and integrative high-throughput technologies, organoids are poised to revolutionize precision therapy. However, realizing their full translational potential demands concerted efforts in standardization, ethical governance, and cross-disciplinary innovation. The future of cancer modeling and individualized treatment is bright, with tumor organoids at its core.

Subject of Research:
Not applicable

Article Title:
Harnessing human tumor organoids for cancer modeling and precision therapy

News Publication Date:
16-Feb-2026

Image Credits:
HIGHER EDUCATION PRESS

NP137 operates through the blockade of netrin1, a molecule intricately linked with cellular processes that cancer cells exploit to evade chemotherapy. By inhibiting netrin1, NP137 fundamentally alters the tumor microenvironment, making cancer cells more susceptible to conventional chemotherapy regimens. This strategy diverges from traditional approaches that solely aim at directly killing tumor cells, positioning NP137 as a pioneering agent that sensitizes tumors via molecular modulation.

The combinatorial regimen of NP137 with mFOLFIRINOX—a chemotherapy protocol comprised of folinic acid, fluorouracil, irinotecan, and oxaliplatin—has demonstrated encouraging safety profiles and clinical activity in early-phase trials involving patients with locally advanced PDAC. Mechanistic insights derived from extensive translational analyses underscore the uniqueness of NP137’s mode of action. These findings prompt a reevaluation of netrin1’s role in tumorigenesis and resistance, suggesting it as a promising therapeutic target.

Central to this innovation is the concept of epithelial-to-mesenchymal transition (EMT), a biological process where cancer cells acquire migratory and invasive characteristics that propagate metastatic spread and therapeutic resistance. The Lap-NET1 clinical study has specifically focused on patients with locally advanced PDAC under the premise that EMT drives the metastatic cascade. By intervening in this process via netrin1 blockade, NP137 may inhibit a fundamental mechanism fueling pancreatic tumor aggressiveness.

The significance of EMT extends beyond localized tumors, as evidence suggests its activity persists within metastatic lesions. This insight provokes the hypothesis that patients afflicted with metastatic PDAC could also benefit from NP137 combined with chemotherapy, potentially broadening the therapeutic window for patients previously deemed refractory to available treatments. Such an approach signals a paradigm shift in the management of advanced pancreatic cancer.

The next milestone for NP137 is its evaluation in a randomized phase 2 trial that will investigate its integration with the current standard of care for first-line treatment in metastatic PDAC patients. This trial is designed not only to verify efficacy and safety but also to critically explore the predictive capability of a neogenin immunohistochemistry (IHC) test. The neogenin marker may serve as a biomarker to identify patients who stand to gain the most therapeutic benefit from NP137—the epitome of precision medicine.

While the initial clinical outcomes are optimistic, the journey toward integrating NP137 into standard clinical practice depends on robust validation. The randomized phase 2 study will provide pivotal data to determine whether NP137’s addition extends overall survival, improves quality of life, and possibly delays or prevents disease progression. Success here could herald a novel therapeutic avenue for PDAC, where historically survival rates have remained dismal despite numerous trials.

Further translational research reveals that netrin1’s blockade does not merely ‘disable’ the tumor cells but dynamically remodels the tumor microenvironment, potentially impairing the supportive stroma that often shelters cancer cells from cytotoxic agents. By reprogramming this hostile niche, NP137 may enhance drug delivery and efficacy, illustrating the multifaceted impact of this therapeutic strategy.

Notably, the safety profile emerging from the initial studies highlights a tolerable adverse event spectrum, an essential consideration given the often debilitating side effects associated with combination chemotherapy. By minimizing additive toxicity, NP137 positions itself as an adjunct therapy that could be feasibly incorporated into existing treatment protocols without compromising patient safety.

The discovery and development of NP137 align with the growing movement toward biomarker-driven oncology, where treatments are tailored based on individual molecular landscapes. Utilizing neogenin IHC tests to select patients exemplifies this tailored approach, optimizing therapeutic response while sparing non-responders from unnecessary treatment burdens.

This scientific advancement also reinvigorates the broader endeavor to unravel the mechanistic underpinnings of chemotherapy resistance—a phenomenon that transcends pancreatic cancer and impacts many malignancies. Understanding how netrin1 signaling intertwines with EMT and cellular resilience opens avenues for potentially applicable cross-cancer therapies.

Beyond the immediate clinical implications, the introduction of NP137 raises compelling questions for future research. Could netrin1 blockade synergize with emerging immunotherapies? Might combining NP137 with other targeted agents amplify therapeutic benefits? The unfolding narrative presents fertile ground for subsequent investigations that could reshape oncologic treatment landscapes.

Ultimately, the trajectory of NP137—from conceptualization to clinical validation—epitomizes the convergence of molecular biology, translational research, and patient-centric clinical trials. Its promise in dismantling the biochemical fortress of chemotherapy resistance offers hope against one of the deadliest cancers, demanding attention and optimism from the global scientific and medical communities.

As the randomized trials advance, the oncology field watches eagerly to see whether NP137 will fulfill its transformative potential, delivering a much-needed breakthrough in pancreatic cancer therapeutics. For patients and clinicians alike, the hope kindled by this study is a beacon of progress in the relentless battle against cancer.

Subject of Research: Netrin1 blockade in pancreatic ductal adenocarcinoma (PDAC) and its impact on chemotherapy resistance

Article Title: Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer

Article References:
Roth, G., Artru, P., Bouche, O. et al. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10436-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10436-4

The ACC initiative, established in 2011, represents a multi-million-dollar commitment uniting some of the most influential players in cancer research and drug development. Industry partners span a formidable roster, including AbbVie, Amgen, ARIAD, Celgene, Eli Lilly and Company, Genentech, Gilead, Merck, Novartis, Pfizer, and Takeda Pharmaceuticals. This unique partnership underlines the intensified focus on collaborative innovation necessary to combat cancer’s complex molecular and clinical landscape. The synthesis of academic insight with the drug discovery prowess of industry exemplifies a new paradigm in oncology research.

Opening the symposium, Damon Runyon President and CEO Yung S. Lie, PhD, alongside Damon Runyon Board member and BioNTech’s President of Research and Development Richard B. Gaynor, MD, and Amgen’s Executive Vice President of Research and Development James Bradner, MD, set an ambitious tone. Dr. Bradner, himself an alumnus of the Damon Runyon-Rachleff Innovator program, famously dubbed Damon Runyon a “triple-A team,” emphasizing how the foundation nurtures some of the most courageous and innovative scientific talents entering the biopharmaceutical sector.

The symposium featured several cutting-edge presentations from Damon Runyon-supported scientists, who are delving into the intricacies of cancer genomics and gene expression regulation. Mark Yarmarkovich, PhD, Lucas Farnung, PhD, Mary M. Mullen, MD, and Ziyang Zhang, PhD, each shared advances that aim to delineate the molecular signatures of various cancers to design highly precise, targeted therapies. Their work exemplifies the shift from broad-spectrum chemotherapeutics to tailored interventions that exploit tumor-specific vulnerabilities.

A keynote address delivered by Anna Farago, MD, PhD, Vice President of Early Development in Oncology at Amgen, and Julie Bailis, PhD, a former Damon Runyon Fellow and current Vice President of Oncology Research at Amgen, underscored the essential dialogue between preclinical data and clinical trial findings. Dr. Bailis articulated the tremendous value of iterative feedback loops between bench and bedside, a relationship imperative for refining therapeutic candidates and accelerating their journey through development pipelines.

Further illuminating the challenging landscape of difficult-to-treat malignancies, Damon Runyon investigators Megan A. Morrissey, PhD, Srivatsan Raghavan, MD, PhD, and Jonathan Chou, MD, PhD, discussed innovative approaches in combatting refractory cancers, including pancreatic adenocarcinoma. These types of malignancies, notorious for their resistance to conventional therapies and poor prognosis, demand novel therapeutic paradigms informed by deep mechanistic insights, such as targeting tumor microenvironmental factors or exploiting unique metabolic dependencies.

The afternoon session’s fireside chat, expertly moderated by Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences, brought together top translational oncology leaders—Jennifer Lauchte, MD (Novartis), Alex R. Shoemaker, PhD (AbbVie), and Louis Vermeulen, MD, PhD (Genentech). Their candid discussion highlighted the mechanics of successful collaboration in the drug development arena. Dr. Lauchte stressed the necessity of integrating multidisciplinary teams encompassing clinical trialists, molecular biologists, and medicinal chemists to generate comprehensive insights, avoiding siloed approaches that impede progress.

This symposium exemplifies the tangible benefits when academia and industry synchronize efforts to tackle cancer’s complexity. Dr. Lie and Margaret Faul, PhD, Vice President of Drug Substance Technologies and Site Head of Amgen Massachusetts, concluded the day by emphasizing the value of cross-disciplinary collaboration, noting that the Accelerating Cancer Cures initiative models how such partnerships can spur innovative therapeutic breakthroughs.

The ACC program’s strategy is rooted in empowering early-career clinical investigators by providing them with the funding and collaborative networks necessary to pursue high-risk, high-reward translational research. The iterative, bidirectional communication fostered between scientists, clinicians, and industry experts accelerates the identification of actionable biomarkers, validation of therapeutic targets, and the optimization of drug candidates. The promise of this synergy lies in shortening the timeline from scientific discovery to effective patient treatment.

Underlying the discussions at the symposium is an appreciation for the genomic and proteomic heterogeneity that defines malignancies. The presentations underscored the importance of leveraging next-generation sequencing technologies, CRISPR-based functional genomics, and sophisticated computational biology tools to unravel cancer’s molecular complexity. Such approaches enable the development of precision oncology strategies that account for tumor evolution, microenvironmental influences, and immune evasion mechanisms.

Moreover, the symposium shed light on the growing trend of integrating novel modalities, including bispecific antibodies, cell therapies, and targeted protein degraders in cancer therapeutics. These modalities, often emerging from deep academic research programs, require robust translational frameworks to ensure their effective clinical application. The ACC consortium’s commitment to facilitating these translational bridges is vital for capitalizing on these groundbreaking modalities.

In summary, the 2026 Accelerating Cancer Cures Research Symposium not only highlighted the impressive scientific advances driven by Damon Runyon scientists but also exemplified the power of collaborative ecosystems that unite academic ingenuity with industrial development capacity. With relentless dedication and strategic partnerships, the ambitions to transform cancer from a fatal diagnosis into a manageable condition have never been closer to fruition. This event stands as a beacon of hope and an illustration of how concerted collective efforts can accelerate the delivery of transformative cancer therapies to patients worldwide.

Subject of Research: Translational cancer research focused on accelerating discovery and development of targeted therapies through collaboration between academia and industry.

Article Title: Accelerating Cancer Cures: The 2026 Damon Runyon Symposium Sparks Dynamic Innovation in Oncology Therapeutics

News Publication Date: March 24, 2026

Web References:
– https://www.damonrunyon.org/
– https://www.amgen.com/
– https://www.novartis.com/
– https://www.genentech.com/
– https://www.abbvie.com/

Keywords: cancer genomics, targeted therapies, translational research, clinical innovation, collaboration, Damon Runyon, Accelerating Cancer Cures, oncology, pharmaceutical industry, molecular oncology, precision medicine, drug development

Despite the imperative for innovation, clinical hesitancy remains pervasive due to the absence of reliable biomarkers that can predict patient responses early in the treatment course. Clinicians find themselves constrained by the unpredictability of novel therapies, limiting their willingness to deviate from established regimens that, while imperfect, remain the gold standard.

A groundbreaking study conducted by researchers at the Cummings School of Veterinary Medicine at Tufts University in collaboration with UMass Chan Medical School now illuminates a promising strategy to circumvent these barriers. By leveraging the unique biological parallels in pet dogs naturally afflicted with DLBCL, the study explores how blood-based immune gene expression signatures can serve as early indicators of long-term survivorship and treatment efficacy.

The research employed samples collected from a randomized clinical trial involving canine subjects subjected to three experimental treatment protocols. Each protocol incorporated a canine analog of the therapeutic antibody used in humans, paired with a reduced dose of doxorubicin—one of the traditional chemotherapy components—to mitigate toxicity. Subsequently, dogs received one of three novel immunotherapy treatments designed to stimulate the immune system’s anti-cancer response. Notably, two of these immunotherapies are currently being evaluated in human clinical trials, underscoring the translational potential of these findings.

Rather than examining tumor biopsies, the investigators focused on peripheral blood mononuclear cells (PBMCs), harnessing a minimally invasive “liquid biopsy” technique increasingly recognized in both veterinary and human oncology. By sampling at multiple intervals—prior to treatment, seven days post-initiation but before immunotherapy administration, at the conclusion of the combined chemo-immunotherapy cycle, and at either cancer relapse or 400 days post-treatment for disease-free subjects—the study offers a dynamic portrait of the evolving immune landscape.

Crucial insights emerged when gene expression profiles were stratified based on clinical outcomes. Dogs exhibiting prolonged remission demonstrated elevated activity in two immune-related genes: CD1E and CCL14. CD1E encodes a critical molecule involved in antigen presentation, facilitating the activation of T cells tasked with targeting cancerous cells. CCL14 functions as a chemokine that recruits immune effectors to focal sites of malignancy, enhancing local immune surveillance and response capabilities.

These discoveries imply that robust baseline immune functionality, reflected by heightened CD1E and CCL14 expression, may underpin more favorable therapeutic responses. Intriguingly, therapeutic response appeared independent of the specific immunotherapy administered, suggesting that preexisting immune competence, rather than the particular immunomodulatory agent, dictates long-term outcomes.

Equally unexpected was the identification of a detrimental role for certain interferon-stimulated genes (ISGs), traditionally regarded as anti-cancer mediators. Interferons, as cytokines, orchestrate immune cell communication and bolster anti-tumor activity. However, in this context of blood cancer, elevated ISG activity correlated with worse prognoses, including abbreviated survival and rapid relapse. This paradoxical finding challenges entrenched paradigms, hinting that interferon signaling might inadvertently foster the survival and proliferative capacity of lymphoma cells in some cases.

Further, the team pinpointed three specific genes—TBHD, NPNT, and ISG20—whose upregulation within just one week of treatment initiation reliably predicted poorer outcomes. Capitalizing on this, Heather Gardner, co-senior author and expert in veterinary oncology diagnostics, devised a streamlined laboratory assay capable of detecting these gene expression changes in clinical settings, offering a practical tool to enhance early prognostic assessments.

The translational implications of this work are profound. A blood-based test applied early during treatment could empower veterinarians—and potentially human oncologists—to identify patients at elevated risk of relapse. This would enable timely therapeutic adjustments, potentially improving survival rates and diminishing unnecessary exposure to toxic agents.

Cheryl London, co-senior author and distinguished professor in comparative oncology, emphasizes the intent to validate whether guiding treatment decisions through this biomarker assay can tangibly extend survival among dogs suffering from lymphoma. Such validation would pave the way for analogous strategies in human medicine, where reducing chemotherapy-induced toxicity without compromising efficacy remains a paramount objective.

The study exemplifies the power of comparative oncology, using insights from naturally occurring cancers in companion animals to inform human clinical research. By capturing the complex interplay between the immune system and cancer, it expands the frontier of precision medicine, heralding a future where treatment is tailored not only to the tumor’s characteristics but also to the host’s immune milieu.

As these findings echo across disciplines, they raise compelling questions about the nuanced roles of immune pathways in cancer progression and response. They further underscore the necessity of revisiting established biological dogmas within specific disease contexts to unlock more effective and less harmful cancer therapies.

Supported by NIH funding and published in Scientific Reports, this research exemplifies the collaborative potential between veterinary and human medicine, illustrating how cross-species investigations can reveal biomarkers and therapeutic avenues of mutual benefit.

Subject of Research: Animals

Article Title: Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL

News Publication Date: 25-Mar-2026

Web References:
– https://rdcu.be/e9YUf
– http://dx.doi.org/10.1038/s41598-026-44677-0

References: Research supported by NIH under award numbers U01CA224153-01 and K01OD028268-01A1; details in Scientific Reports publication.

Keywords: Diffuse large B-cell lymphoma, canine lymphoma, immunotherapy, gene expression, liquid biopsy, immune biomarkers, interferon-stimulated genes, chemotherapy toxicity, translational oncology, comparative oncology, peripheral blood mononuclear cells, precision medicine

The crux of this venture lies in the deployment of Insilico Medicine’s PandaOmics platform, a sophisticated AI-powered biological data analysis suite. Designed to transcend traditional methodologies, PandaOmics integrates an array of over twenty proprietary AI and bioinformatic models, orchestrating a comprehensive evaluation of multi-omics data along with biomedical textual information. This integration facilitates the identification and prioritization of druggable targets rooted in deep biological insights and translational potential, thus streamlining the complex arena of target discovery.

MSK’s unparalleled repository of multi-omic clinical data forms a foundational pillar for the joint effort. Their contributions encompass high-resolution genomic, proteomic, and transcriptomic datasets accompanied by meticulously annotated patient cohorts. This wealth of data provides a robust framework for discerning pathogenic drivers across diverse gastroesophageal cancer subtypes, an endeavor crucial for tailoring therapies to the heterogeneous patient population afflicted with these aggressive malignancies.

The collaborative project is initiating with rigorous data acquisition, quality control, and integration processes, ensuring that the datasets fed into PandaOmics are both comprehensive and accurate. Following this foundational phase, the initiative will progress to AI-enabled hypothesis generation, in which potential therapeutic targets will be systematically ranked and scrutinized through extensive biological investigations. This stratified approach ensures that only the most promising targets advance toward the drug development pipeline.

One of the profound ambitions of the partnership is to facilitate rapid translation of these discoveries into viable therapeutic candidates. This includes comprehensive evaluation of identified targets within various modalities, encompassing both biologics and small molecule approaches. Such versatility augments the potential to address the diverse molecular underpinnings characteristic of gastroesophageal cancers, which have historically been challenging to treat effectively.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, emphasizes the transformative nature of this integration, highlighting how coupling MSK’s clinical excellence with AI sophistication could unlock unprecedented biological insights. Gastroesophageal cancers represent a formidable clinical challenge due to their complexity and poor prognoses, and this collaboration endeavors to usher in a new era of precision medicine that transcends existing therapeutic limitations.

Dr. Janjigian further elucidates the vision, underscoring the necessity for personalized breakthroughs derived from an intricate understanding of individual disease biology. The integration of patient-level clinical and molecular data with AI’s analytic prowess promises a dynamic platform for real-time insights, facilitating the swift identification and clinical deployment of targeted therapies tailored to individual patient profiles.

Insilico Medicine’s track record further solidifies confidence in this initiative. The company has consistently demonstrated the prowess of AI in expediting early-stage drug development, achieving preclinical candidate nominations at an unprecedented pace. From 2021 to 2024, Insilico has nominated twenty preclinical candidates, each within an average of merely 12 to 18 months since project initiation—a dramatic acceleration compared to traditional timelines spanning multiple years.

The PandaOmics platform’s integration of machine learning, deep learning, and advanced bioinformatics is instrumental in this efficiency. By synthesizing voluminous datasets into actionable insights, the platform deftly navigates the enormous biological complexity inherent in multi-omic landscapes, discerning patterns and correlations imperceptible to conventional analytical methods. This facilitates the pinpointing of high-value therapeutic targets, mitigating the attrition rates that have long plagued drug development pipelines.

One innovative aspect of this collaboration involves the dynamic feedback loop between AI predictions and empirical biological validation. This iterative model ensures that hypotheses generated in silico undergo rigorous experimental scrutiny, refining the accuracy of target prioritization and expediting the translation from computational predictions to clinically relevant interventions.

Given the heterogeneity of gastroesophageal tumors, understanding molecular drivers at a granular level is paramount for effective therapy design. By melding AI’s computational power with comprehensive patient data, this partnership aims to uncover subtype-specific vulnerabilities and resistance mechanisms, paving the way for interventions that are not only effective but also resilient against tumor evolution.

As this collaboration advances, it holds the promise of not only transforming therapeutic discovery for gastroesophageal cancers but also setting a precedent for AI-driven innovations across oncology and beyond. The fusion of state-of-the-art computational technology with elite clinical resources exemplifies a paradigm shift toward more efficient, precise, and personalized medicine.

Insilico Medicine’s commitment to integrating AI and automation into drug discovery heralds a new chapter in biomedical innovation, addressing critical unmet medical needs across oncology, immunology, metabolic disorders, and more. Their public listing on the Hong Kong Stock Exchange underscores the global recognition of AI’s transformative impact on health sciences and longevity.

Ultimately, this alliance illustrates how multidisciplinary collaboration, powered by AI and enriched clinical data, can break historical barriers in complex disease research. Patients afflicted by gastroesophageal malignancies may soon benefit from therapies born out of this synergy, marking a hopeful horizon in the fight against these formidable cancers.

Subject of Research: Novel therapeutic target discovery for gastroesophageal cancers using AI-driven platforms and multi-omic clinical datasets.

Article Title: Insilico Medicine and Memorial Sloan Kettering Launch AI-Powered Initiative to Transform Gastroesophageal Cancer Therapeutics

News Publication Date: February 17, 2025

Web References:
http://www.insilico.com

Image Credits: Insilico Medicine

Keywords: Life sciences, Research methods, Scientific community, Health and medicine

The emerging paradigm demands an integrative approach, where biology, technology, and clinical applications intersect seamlessly. To facilitate this integration, the new journal Advanced Cancer Research has been established as an international, peer-reviewed platform dedicated to publishing high-caliber research encompassing basic science, translational studies, and clinical trials. The journal’s mission is to prioritize contributions that not only delve into the mechanistic underpinnings of cancer but also drive conceptual innovation and technological breakthroughs. With a sharp focus on research that traverses disciplinary boundaries, it aims to catalyze advances that directly inform therapeutic development.

The scientific scope of Advanced Cancer Research reflects the convergent and interdisciplinary nature of modern oncology. It invites submissions across a broad spectrum of fields—from cancer molecular biology and genomics to the tumor microenvironment and metastasis. Particularly emphasized are studies exploring cancer heterogeneity and stem cell plasticity, which are pivotal in understanding tumor evolution and therapeutic resistance. The journal also highlights emergent domains such as the interplay between cancer and the microbiome, aging biology, synthetic and structural biology, and the incorporation of artificial intelligence and machine learning to decode complex oncogenic pathways.

Innovative experimental models receive particular attention, including the development and application of organoids, organ-on-chip systems, and advanced three-dimensional tumor models. These cutting-edge platforms recapitulate the tumor microenvironment more accurately than traditional two-dimensional cultures, bridging the gap between in vitro studies and in vivo physiology. Moreover, multi-omics approaches integrating genomics, transcriptomics, proteomics, and metabolomics data open new avenues for systemic insight, enabling the identification of novel biomarkers and therapeutic targets.

One of the cardinal tenets underpinning the journal’s philosophy is the recognition that cancer research cannot be siloed. Rather than compartmentalizing molecular discoveries, experimental models, or clinical observations as isolated entities, Advanced Cancer Research aspires to forge synergies that connect these dimensions. This integrative outlook is crucial for translating complex biological phenomena into effective treatment strategies that address cancer’s inherent heterogeneity and adaptive capabilities.

The editorial process at Advanced Cancer Research reflects a commitment to rigor, transparency, and inclusivity. Employing a stringent peer review system, the journal assesses each submission based on scientific merit, originality, and potential impact. Methodological precision, ethical compliance, and reproducibility are core criteria, ensuring published works stand up to the highest standards of scientific integrity. Open access publishing enhances the reach and impact of research findings, facilitating unrestricted dissemination to researchers, clinicians, and stakeholders worldwide.

As cancer is a global challenge, the journal draws on a diverse editorial board composed of leading researchers and clinicians from across continents, including representation from the United States, United Kingdom, China, South Korea, Japan, and Singapore. This diverse panel ensures comprehensive expertise and a broad perspective that reflects the international nature of oncology research today. The global approach strengthens the platform’s ability to address regional variations in cancer biology and treatment paradigms.

Supporting the next generation of cancer scientists is a cornerstone of the journal’s vision. Recognizing that innovation often springs from early-career investigators, Advanced Cancer Research actively encourages submissions from emerging researchers who bring fresh outlooks and novel methodologies. Through constructive and developmental peer review, the journal fosters a nurturing environment where promising work can reach its full potential, contributing to the evolving landscape of oncology.

In addition to foundational biology, the journal champions research at the intersection of cancer science and the latest technological developments. The integration of artificial intelligence and machine learning offers unprecedented opportunities to analyze vast datasets, uncover hidden patterns, and accelerate hypothesis generation. Similarly, advances in nanomedicine open new frontiers in targeted drug delivery and diagnostic precision. These intersecting technologies hold the promise to revolutionize cancer treatment by personalizing therapy at an individual patient level.

The tumor microenvironment, including the immune landscape, is a critical focus of translational research featured within the journal. Immunotherapy, now a staple in cancer treatment, continues to evolve, with new modalities aiming to overcome resistance and enhance efficacy. Understanding how metabolic reprogramming, epigenetic modifications, and cell-cell interactions within the microenvironment drive cancer progression is key to developing these next-generation therapies. Likewise, the role of senescence and aging in cancer incidence and response to therapy are topical themes expanding the conceptual framework.

Liquid biopsy technologies, offering minimally invasive means to monitor tumor dynamics via blood or other bodily fluids, exemplify the translational innovations the journal seeks to highlight. These tools facilitate real-time tracking of tumor evolution, treatment response, and resistance mechanisms, potentially transforming clinical decision-making. Coupled with sophisticated computational analysis, the integration of liquid biopsy data into patient management represents a leap toward precision oncology.

In sum, Advanced Cancer Research positions itself as a vital crucible where integrative and forward-looking cancer research can unfold. The journal aspires to be a nexus for critical appraisal, open discourse, and collaborative innovation, channeling the synergy of diverse scientific domains to accelerate the translation of knowledge into tangible patient benefits. As oncology continues its rapid evolution, this platform offers an indispensable venue for shaping the future trajectory of cancer research and therapy.

Subject of Research: Not applicable
Article Title: Advanced Cancer Research: defining a platform for convergent oncology
News Publication Date: 28-Jan-2026
Web References: http://dx.doi.org/10.55092/acr20260001
References: Dong Z. Advanced Cancer Research: defining a platform for convergent oncology. Adv. Cancer Res. 2026(1):0001
Keywords: Cancer, molecular biology, genomics, immunotherapy, tumor microenvironment, cancer heterogeneity, stem cell plasticity, artificial intelligence, machine learning, liquid biopsy, organoids, nanomedicine